Mechanical Thrombectomy Under Fluoroscopy: Outcomes and Evidence
Mechanical thrombectomy performed under fluoroscopic guidance for acute ischemic stroke due to large vessel occlusion significantly improves functional independence and reduces mortality compared to medical management alone, with the technical goal being mTICI 2b/3 reperfusion to maximize favorable outcomes.
Core Evidence for Mechanical Thrombectomy Outcomes
The most recent and comprehensive guidelines establish that mechanical thrombectomy (MT) is the standard of care for large vessel occlusion (LVO) stroke, with fluoroscopy being the standard imaging modality used during these procedures 1, 2.
Primary Functional Outcomes
For patients meeting standard criteria (ICA or M1 occlusion, ASPECTS ≥6, NIHSS ≥6, mRS 0-1 pre-stroke), MT within 6 hours achieves:
- Functional independence (mRS 0-2) in approximately 46-49% of patients versus 13-17% with medical management alone 1
- Number needed to treat of approximately 2-3 patients to achieve one additional functionally independent patient 3
- 58 out of 100 patients will have improved functional status compared to controls 3
Recanalization Success
The technical goal under fluoroscopic guidance is achieving mTICI 2b/3 reperfusion, which directly correlates with improved functional outcomes 4, 1. Recent data shows:
- Successful recanalization (mTICI ≥2b) achieved in 80-85% of cases 5, 6
- First-pass effect in approximately 42% of procedures 5
- Successful recanalization is the strongest predictor of favorable outcome (adjusted OR 19.51,95% CI 2.47-274.05) 5
Extended Time Window Outcomes
The evidence has evolved significantly regarding late-window thrombectomy:
For 6-16 hours from last known normal (DEFUSE-3 criteria):
- Functional independence achieved in 44.6% versus 16.7% with medical management (RR 2.67,95% CI 1.60-4.48) 1
For 16-24 hours from last known normal (DAWN criteria):
- Functional independence achieved in 49% versus 13% with medical management (adjusted difference 33%, 95% CI 21-44) 1
Beyond 24 hours (emerging evidence):
- Recent data suggests comparable efficacy and safety when performed 24-72 hours from onset in carefully selected patients, though this remains outside standard guideline recommendations 7
Safety Profile Under Fluoroscopy
Symptomatic intracranial hemorrhage rates:
- 3.3-11% across contemporary series 5, 6
- No significant increase compared to medical management in most trials 1
Mortality outcomes:
- 90-day mortality of 7.5-22.1% overall 5, 6
- Significantly reduced mortality compared to medical management in appropriately selected patients 1
Procedural Technical Considerations
Stent retrievers are preferred over older devices (Class I, Level A) 4, 1. The use of:
- Proximal balloon guide catheters or large-bore distal access catheters may improve outcomes (Class IIa) 4
- Aspiration techniques (ADAPT) show comparable or superior results to stent retrievers in some series 8
Critical Pitfall to Avoid
Do not delay thrombectomy to observe response to IV tPA - this is explicitly not recommended (Class III) 4. Proceed directly to thrombectomy in eligible patients without waiting for IV thrombolysis response.
Outcomes by Vessel Location
M1 segment MCA occlusions: Standard indication with robust evidence 1, 9
Dominant M2 segment occlusions: Reasonable to perform (Class IIa), though benefits are less certain (OR 1.28,95% CI 0.51-3.21 in pooled analysis) 1
Nondominant M2, distal MCA, ACA, PCA: Not recommended - no demonstrated benefit (Class III: No Benefit) 2
Basilar artery occlusions: May be reasonable on case-by-case basis, though evidence is weaker (Grade C) 9
Large Core Infarct Outcomes
Recent trials (RESCUE-Japan LIMIT, ANGEL-ASPECT, SELECT2, TENSION, TESLA, LASTE) demonstrate that even with large core infarcts (ASPECTS <6 or core volume >50mL), MT improves functional independence:
- Combined OR 1.57 (95% CI 1.40-1.76) for favorable shift in mRS 10
- 19.5% achieved functional independence versus 7.5% with medical management 10
- Mortality benefit of 5.3% absolute risk reduction 10
Important Caveat for Large Cores
CT hypodensity volume ≥26 mL (defined as ≤26 Hounsfield units) was associated with no functional benefit and increased risks including cerebral edema in SELECT2 analysis 2, 10
Special Populations Under Fluoroscopy
Octogenarians and nonagenarians: Should not be excluded; evaluate case-by-case (Class IIa-b) 3. Benefits demonstrated across age groups, though absolute outcomes are worse in very elderly 1
Pregnant patients: MT is safe and feasible; use full fluoroscopic radiation safety features and low threshold for anesthesia consultation (Class IIa-b) 3
Thrombocytopenic patients: Should not be excluded from MT; no absolute platelet threshold, though <20,000 raises significant concern 3
Active cancer patients with ECOG-PS 0: Comparable outcomes to non-cancer patients; those with ECOG-PS ≥1 have significantly worse outcomes 11
Predictors of Favorable Outcome
Independent predictors identified across studies:
- Successful recanalization (mTICI ≥2b) - strongest predictor
- Lower baseline NIHSS score (OR 0.87 per point decrease)
- Absence of diabetes mellitus (aOR 6.22)
- Red/mixed thrombus composition versus white thrombus (aOR 3.06)
- Higher baseline ASPECTS
- Younger age 5
Algorithm for Decision-Making
Within 6 hours:
- ICA or M1 occlusion + NIHSS ≥6 + ASPECTS ≥6 + mRS 0-1 → Proceed with MT (Class I)
- Dominant M2 occlusion meeting above criteria → Reasonable to proceed (Class IIa)
- mRS 2 pre-stroke → Reasonable to proceed (Class IIa)
- mRS 3-4 pre-stroke → May be reasonable (Class IIb)
6-24 hours:
- Must meet DAWN or DEFUSE-3 criteria strictly - do not extrapolate beyond these specific eligibility requirements 1
- DAWN criteria (6-24 hours): Clinical-imaging mismatch based on age, NIHSS, and infarct volume
- DEFUSE-3 criteria (6-16 hours): Perfusion-core mismatch with maximum core size limits
Beyond 24 hours:
- Not currently recommended by guidelines, though emerging evidence suggests potential benefit in highly selected cases 7